The global Antibody-drug Conjugate (ADC) Payload market projected to hit US$ 1796 million in 2025 to US$ 2975 million in 2031; it is expected to grow at a CAGR of 8.8% from 2025 to 2031.

Global Antibody-drug Conjugate (ADC) Payload Market Trends and Analysis 2025-31

The global Antibody-drug Conjugate (ADC) Payload market size is predicted to grow from US$ 1796 million in 2025 to US$ 2975 million in 2031; it is expected to grow at a CAGR of 8.8% from 2025 to 2031. Antibody-drug Conjugate (ADC) Payload refers to a cytotoxic drug or bioactive molecule that is bound to an antibody. This payload is a key component of the ADC and is responsible for exerting an anti-tumor effect in the target cell to achieve a therapeutic effect. The design and selection of the payload directly affects the therapeutic effect and safety of the ADC and is an important part of achieving targeted therapy. United States market for Antibody-drug Conjugate (ADC) Payload is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. China market for Antibody-drug Conjugate (ADC) Payload is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Europe market for Antibody-drug Conjugate (ADC) Payload is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Global key Antibody-drug Conjugate (ADC) Payload players cover Lonza, Veranova, Merck, Cerbios-Pharma SA, Porton Pharma Solutions, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024. Infinity Market Research newest research report, the Antibody-drug Conjugate (ADC) Payload Industry Forecast looks at past sales and reviews total world Antibody-drug Conjugate (ADC) Payload sales in 2024, providing a comprehensive analysis by region and market sector of projected Antibody-drug Conjugate (ADC) Payload sales for 2025 through 2031. With Antibody-drug Conjugate (ADC) Payload sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-drug Conjugate (ADC) Payload industry. This Insight Report provides a comprehensive analysis of the global Antibody-drug Conjugate (ADC) Payload landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antibody-drug Conjugate (ADC) Payload portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Antibody-drug Conjugate (ADC) Payload market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-drug Conjugate (ADC) Payload and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-drug Conjugate (ADC) Payload. This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-drug Conjugate (ADC) Payload market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Tumor Specificity &nbsp;&nbsp;&nbsp; Broadly Targeted Segmentation by Application: &nbsp;&nbsp;&nbsp; Pharmaceuticals &nbsp;&nbsp;&nbsp; Scientific Research This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Lonza &nbsp;&nbsp;&nbsp; Veranova &nbsp;&nbsp;&nbsp; Merck &nbsp;&nbsp;&nbsp; Cerbios-Pharma SA &nbsp;&nbsp;&nbsp; Porton Pharma Solutions &nbsp;&nbsp;&nbsp; Ajinomoto Bio-Pharma &nbsp;&nbsp;&nbsp; Teva Pharmaceutical Industries Ltd. &nbsp;&nbsp;&nbsp; Abzena &nbsp;&nbsp;&nbsp; Sterling Pharma Solutions Limited &nbsp;&nbsp;&nbsp; Indena &nbsp;&nbsp;&nbsp; Pfizer &nbsp;&nbsp;&nbsp; CordenPharma &nbsp;&nbsp;&nbsp; Heraeus Precious Metals &nbsp;&nbsp;&nbsp; Novasep &nbsp;&nbsp;&nbsp; Shanghai Haoyuan Chemexpress Co. Ltd. &nbsp;&nbsp;&nbsp; Minakem Key Questions Addressed in this Report What is the 10-year outlook for the global Antibody-drug Conjugate (ADC) Payload market? What factors are driving Antibody-drug Conjugate (ADC) Payload market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Antibody-drug Conjugate (ADC) Payload market opportunities vary by end market size? How does Antibody-drug Conjugate (ADC) Payload break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Antibody-drug Conjugate (ADC) Payload Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Antibody-drug Conjugate (ADC) Payload by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Antibody-drug Conjugate (ADC) Payload by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Antibody-drug Conjugate (ADC) Payload Segment by Type &nbsp;2.2.1 Tumor Specificity &nbsp;2.2.2 Broadly Targeted &nbsp;2.3 Antibody-drug Conjugate (ADC) Payload Sales by Type &nbsp;2.3.1 Global Antibody-drug Conjugate (ADC) Payload Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Antibody-drug Conjugate (ADC) Payload Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Antibody-drug Conjugate (ADC) Payload Sale Price by Type (2020-2025) &nbsp;2.4 Antibody-drug Conjugate (ADC) Payload Segment by Application &nbsp;2.4.1 Pharmaceuticals &nbsp;2.4.2 Scientific Research &nbsp;2.5 Antibody-drug Conjugate (ADC) Payload Sales by Application &nbsp;2.5.1 Global Antibody-drug Conjugate (ADC) Payload Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Antibody-drug Conjugate (ADC) Payload Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Antibody-drug Conjugate (ADC) Payload Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Antibody-drug Conjugate (ADC) Payload Breakdown Data by Company &nbsp;3.1.1 Global Antibody-drug Conjugate (ADC) Payload Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Antibody-drug Conjugate (ADC) Payload Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Antibody-drug Conjugate (ADC) Payload Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Antibody-drug Conjugate (ADC) Payload Revenue by Company (2020-2025) &nbsp;3.2.2 Global Antibody-drug Conjugate (ADC) Payload Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Antibody-drug Conjugate (ADC) Payload Sale Price by Company &nbsp;3.4 Key Manufacturers Antibody-drug Conjugate (ADC) Payload Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Antibody-drug Conjugate (ADC) Payload Product Location Distribution &nbsp;3.4.2 Players Antibody-drug Conjugate (ADC) Payload Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Antibody-drug Conjugate (ADC) Payload by Geographic Region &nbsp;4.1 World Historic Antibody-drug Conjugate (ADC) Payload Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Antibody-drug Conjugate (ADC) Payload Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Antibody-drug Conjugate (ADC) Payload Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Antibody-drug Conjugate (ADC) Payload Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Antibody-drug Conjugate (ADC) Payload Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Antibody-drug Conjugate (ADC) Payload Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Antibody-drug Conjugate (ADC) Payload Sales Growth &nbsp;4.4 APAC Antibody-drug Conjugate (ADC) Payload Sales Growth &nbsp;4.5 Europe Antibody-drug Conjugate (ADC) Payload Sales Growth &nbsp;4.6 Middle East & Africa Antibody-drug Conjugate (ADC) Payload Sales Growth 5 Americas &nbsp;5.1 Americas Antibody-drug Conjugate (ADC) Payload Sales by Country &nbsp;5.1.1 Americas Antibody-drug Conjugate (ADC) Payload Sales by Country (2020-2025) &nbsp;5.1.2 Americas Antibody-drug Conjugate (ADC) Payload Revenue by Country (2020-2025) &nbsp;5.2 Americas Antibody-drug Conjugate (ADC) Payload Sales by Type (2020-2025) &nbsp;5.3 Americas Antibody-drug Conjugate (ADC) Payload Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Antibody-drug Conjugate (ADC) Payload Sales by Region &nbsp;6.1.1 APAC Antibody-drug Conjugate (ADC) Payload Sales by Region (2020-2025) &nbsp;6.1.2 APAC Antibody-drug Conjugate (ADC) Payload Revenue by Region (2020-2025) &nbsp;6.2 APAC Antibody-drug Conjugate (ADC) Payload Sales by Type (2020-2025) &nbsp;6.3 APAC Antibody-drug Conjugate (ADC) Payload Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Antibody-drug Conjugate (ADC) Payload by Country &nbsp;7.1.1 Europe Antibody-drug Conjugate (ADC) Payload Sales by Country (2020-2025) &nbsp;7.1.2 Europe Antibody-drug Conjugate (ADC) Payload Revenue by Country (2020-2025) &nbsp;7.2 Europe Antibody-drug Conjugate (ADC) Payload Sales by Type (2020-2025) &nbsp;7.3 Europe Antibody-drug Conjugate (ADC) Payload Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Antibody-drug Conjugate (ADC) Payload by Country &nbsp;8.1.1 Middle East & Africa Antibody-drug Conjugate (ADC) Payload Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Antibody-drug Conjugate (ADC) Payload Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Antibody-drug Conjugate (ADC) Payload Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Antibody-drug Conjugate (ADC) Payload Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Antibody-drug Conjugate (ADC) Payload &nbsp;10.3 Manufacturing Process Analysis of Antibody-drug Conjugate (ADC) Payload &nbsp;10.4 Industry Chain Structure of Antibody-drug Conjugate (ADC) Payload 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Antibody-drug Conjugate (ADC) Payload Distributors &nbsp;11.3 Antibody-drug Conjugate (ADC) Payload Customer 12 World Forecast Review for Antibody-drug Conjugate (ADC) Payload by Geographic Region &nbsp;12.1 Global Antibody-drug Conjugate (ADC) Payload Market Size Forecast by Region &nbsp;12.1.1 Global Antibody-drug Conjugate (ADC) Payload Forecast by Region (2026-2031) &nbsp;12.1.2 Global Antibody-drug Conjugate (ADC) Payload Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Antibody-drug Conjugate (ADC) Payload Forecast by Type (2026-2031) &nbsp;12.7 Global Antibody-drug Conjugate (ADC) Payload Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Lonza &nbsp;13.1.1 Lonza Company Information &nbsp;13.1.2 Lonza Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.1.3 Lonza Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Lonza Main Business Overview &nbsp;13.1.5 Lonza Latest Developments &nbsp;13.2 Veranova &nbsp;13.2.1 Veranova Company Information &nbsp;13.2.2 Veranova Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.2.3 Veranova Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Veranova Main Business Overview &nbsp;13.2.5 Veranova Latest Developments &nbsp;13.3 Merck &nbsp;13.3.1 Merck Company Information &nbsp;13.3.2 Merck Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.3.3 Merck Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Merck Main Business Overview &nbsp;13.3.5 Merck Latest Developments &nbsp;13.4 Cerbios-Pharma SA &nbsp;13.4.1 Cerbios-Pharma SA Company Information &nbsp;13.4.2 Cerbios-Pharma SA Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.4.3 Cerbios-Pharma SA Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Cerbios-Pharma SA Main Business Overview &nbsp;13.4.5 Cerbios-Pharma SA Latest Developments &nbsp;13.5 Porton Pharma Solutions &nbsp;13.5.1 Porton Pharma Solutions Company Information &nbsp;13.5.2 Porton Pharma Solutions Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.5.3 Porton Pharma Solutions Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Porton Pharma Solutions Main Business Overview &nbsp;13.5.5 Porton Pharma Solutions Latest Developments &nbsp;13.6 Ajinomoto Bio-Pharma &nbsp;13.6.1 Ajinomoto Bio-Pharma Company Information &nbsp;13.6.2 Ajinomoto Bio-Pharma Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.6.3 Ajinomoto Bio-Pharma Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Ajinomoto Bio-Pharma Main Business Overview &nbsp;13.6.5 Ajinomoto Bio-Pharma Latest Developments &nbsp;13.7 Teva Pharmaceutical Industries Ltd. &nbsp;13.7.1 Teva Pharmaceutical Industries Ltd. Company Information &nbsp;13.7.2 Teva Pharmaceutical Industries Ltd. Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.7.3 Teva Pharmaceutical Industries Ltd. Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Teva Pharmaceutical Industries Ltd. Main Business Overview &nbsp;13.7.5 Teva Pharmaceutical Industries Ltd. Latest Developments &nbsp;13.8 Abzena &nbsp;13.8.1 Abzena Company Information &nbsp;13.8.2 Abzena Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.8.3 Abzena Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Abzena Main Business Overview &nbsp;13.8.5 Abzena Latest Developments &nbsp;13.9 Sterling Pharma Solutions Limited &nbsp;13.9.1 Sterling Pharma Solutions Limited Company Information &nbsp;13.9.2 Sterling Pharma Solutions Limited Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.9.3 Sterling Pharma Solutions Limited Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Sterling Pharma Solutions Limited Main Business Overview &nbsp;13.9.5 Sterling Pharma Solutions Limited Latest Developments &nbsp;13.10 Indena &nbsp;13.10.1 Indena Company Information &nbsp;13.10.2 Indena Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.10.3 Indena Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Indena Main Business Overview &nbsp;13.10.5 Indena Latest Developments &nbsp;13.11 Pfizer &nbsp;13.11.1 Pfizer Company Information &nbsp;13.11.2 Pfizer Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.11.3 Pfizer Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Pfizer Main Business Overview &nbsp;13.11.5 Pfizer Latest Developments &nbsp;13.12 CordenPharma &nbsp;13.12.1 CordenPharma Company Information &nbsp;13.12.2 CordenPharma Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.12.3 CordenPharma Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 CordenPharma Main Business Overview &nbsp;13.12.5 CordenPharma Latest Developments &nbsp;13.13 Heraeus Precious Metals &nbsp;13.13.1 Heraeus Precious Metals Company Information &nbsp;13.13.2 Heraeus Precious Metals Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.13.3 Heraeus Precious Metals Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Heraeus Precious Metals Main Business Overview &nbsp;13.13.5 Heraeus Precious Metals Latest Developments &nbsp;13.14 Novasep &nbsp;13.14.1 Novasep Company Information &nbsp;13.14.2 Novasep Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.14.3 Novasep Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 Novasep Main Business Overview &nbsp;13.14.5 Novasep Latest Developments &nbsp;13.15 Shanghai Haoyuan Chemexpress Co. Ltd. &nbsp;13.15.1 Shanghai Haoyuan Chemexpress Co. Ltd. Company Information &nbsp;13.15.2 Shanghai Haoyuan Chemexpress Co. Ltd. Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.15.3 Shanghai Haoyuan Chemexpress Co. Ltd. Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.15.4 Shanghai Haoyuan Chemexpress Co. Ltd. Main Business Overview &nbsp;13.15.5 Shanghai Haoyuan Chemexpress Co. Ltd. Latest Developments &nbsp;13.16 Minakem &nbsp;13.16.1 Minakem Company Information &nbsp;13.16.2 Minakem Antibody-drug Conjugate (ADC) Payload Product Portfolios and Specifications &nbsp;13.16.3 Minakem Antibody-drug Conjugate (ADC) Payload Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.16.4 Minakem Main Business Overview &nbsp;13.16.5 Minakem Latest Developments 14 Research Findings and Conclusion

Report	Global Antibody-drug Conjugate (ADC) Payload Market Growth 2025-2031
Selected License	Multi ID: LPI17824

Buyer Information

Order Summary